ClinicaliQ Trial Snapshot
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A — Recruiting • Phase III • NCT07416604.
- Study comparing NXT007 with emicizumab for preventing bleeding in hemophilia A patients aged 12 and over.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia A of any severity (severe, moderate, and mild) with FVIII inhibitors. Conditions: Hemophilia A Interventions: NXT007, Emicizumab Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 360 participants